Tremfya (guselkumab) / J&J 
Welcome,         Profile    Billing    Logout  
 11 Diseases   38 Trials   38 Trials   2596 News 


12345678910111213...3738»
  • ||||||||||  Journal:  Baseline Characteristics and mNAPSI Change from Baseline Scores Through Month (Pubmed Central) -  Apr 23, 2024   
    Trial completion date: Mar 2029 --> Oct 2029 This real-world study showed that patients with moderate-to-severe psoriasis and any severity of concomitant nail involvement had significantly faster and more substantial improvements in nail psoriasis up to month
  • ||||||||||  Retrospective data, Review:  Drug Survival of IL-17 and IL-23 Inhibitors for Psoriasis: A Systematic Review and Meta-Analysis. (Pubmed Central) -  Apr 17, 2024   
    This meta-analysis showed that the investigated IL-17 and IL-23 inhibitors had high drug survival rates, with highest rates for guselkumab and risankizumab drug survival. We showed that effect modifiers such as biologic naivety, and the source of data used (registry/electronic health record data vs pharmacy/claims databases) is relevant when interpreting drug survival studies.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Trial termination:  ORCHID-LN: A Study of Guselkumab in Participants With Active Lupus Nephritis (clinicaltrials.gov) -  Apr 16, 2024   
    P2,  N=33, Terminated, 
    Completed --> Terminated; Due to enrollment challenges, J&J Innovative Medicine decided to stop screening and terminate the study early. This decision was not based on a safety concern.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Review, Journal:  Dose reduction of biologics in patients with plaque psoriasis: a review. (Pubmed Central) -  Apr 12, 2024   
    Four of the newly found articles tested DR strategies, mostly focusing on first-generation biologics; only guselkumab (IL-23i) was included in one study...In conclusion, DR seems promising, but a research gap still exists in randomized, prospective studies testing DR strategies, especially of IL-17/23i, hampering the completion of guidelines on DR. Taking into account the identified barriers and facilitators most likely results in a more successful implementation of biologic DR in practice.
  • ||||||||||  Tremfya (guselkumab) / J&J
    Trial completion:  HiGUS: Guselkumab for Hidradenitis Suppurativa, a Mode of Action Study. (clinicaltrials.gov) -  Apr 4, 2024   
    P2,  N=20, Completed, 
    The head and lower limbs were the areas least responsive to treatment, with PASI Unknown status --> Completed
  • ||||||||||  Taltz (ixekizumab) / Eli Lilly, Japan Tobacco, Tremfya (guselkumab) / J&J
    Retrospective data, Journal:  Drug survival of biologics in psoriasis: An Australian multicentre retrospective study. (Pubmed Central) -  Mar 21, 2024   
    To our knowledge, this is the first Australian study to report on outcomes of multiple new biologics that are currently in use for the treatment of chronic plaque psoriasis. Overall, this study provides insight into patterns of care from a local experience that may help guide the management of moderate-to-severe psoriasis.
  • ||||||||||  Bimzelx (bimekizumab) / UCB, Tremfya (guselkumab) / J&J
    Journal, HEOR:  Comparative Effectiveness of Bimekizumab and Guselkumab in Patients with Psoriatic Arthritis at 52 (Pubmed Central) -  Mar 15, 2024   
    P3, P3b
    Overall, this study provides insight into patterns of care from a local experience that may help guide the management of moderate-to-severe psoriasis. According to MAICs, bimekizumab demonstrated greater or comparable efficacy on ACR50/70 and MDA outcomes than guselkumab in patients with PsA who were bDMARD-na
  • ||||||||||  Skyrizi (risankizumab-rzaa) / AbbVie, Boehringer Ingelheim, Alofisel (darvadstrocel) / Takeda, Tremfya (guselkumab) / J&J
    4435: Immunology, Microbiology & Inflammatory Bowel Diseases (IMIBD) Section Distinguished Abstract Plenary (Ballroom B - Walter E. Washington Convention Center) -  Mar 14, 2024 - Abstract #DDW2024DDW_6013;    
    Description: This session highlights the best of the best in basic and clinical science research submitted to DDW 2024. Learning Objectives: Describe the efficacy and safety of guselkumab, darvadstrocel, and risankizumab for the treatment of IBD
  • ||||||||||  EFFICACY AND SAFETY OF ADVANCED MEDICAL TREATMENTS FOR INDUCTION OF REMISSION IN CROHN'S DISEASE: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS (Hall A) -  Mar 14, 2024 - Abstract #DDW2024DDW_4909;    
    There was moderate certainty of evidence for combination of ADA and azathioprine (AZA) (RR 3.1, 95%CI [2.0-4.8]; risk difference [RD]: 40.1%), IFX+AZA (RR 2.5, 95%CI [1.7-3.8]; RD: 28.9%), ADA (RR 2.5, 95%CI [1.8-3.5]; RD:28.5%), and UST (RR 2.0 95%CI, [1.6-2.5]; RD: 19.2%) in induction of clinical remission compared to placebo...Conclusion On network meta-analysis, combination of anti-TNFs and immunomodulators followed by anti-TNF monotherapy had large effect size with moderate certainty for the induction of clinical remission. More novel therapies appear to have examples of similarly important effect sizes, but are currently limited due to the imprecision of the limited evidence base at present and future research should target these therapies in study
  • ||||||||||  Tremfya (guselkumab) / J&J
    GUSELKUMAB BINDING TO CD64+ IL-23 (Hall A) -  Mar 14, 2024 - Abstract #DDW2024DDW_3199;    
    In in vitro assays GUS, but not RZB, showed Fc-mediated binding to CD64 on IFN?-primed monocytes. CD64-bound GUS simultaneously captured IL-23 secreted from the same cells.
  • ||||||||||  Tremfya (guselkumab) / J&J
    ORAL IL-23R ANTAGONIST MINIPROTEIN MB1 IS AS EFFECTIVE AS GUSELKUMAB IN A PRECLINICAL MODEL OF COLITIS (Hall A) -  Mar 14, 2024 - Abstract #DDW2024DDW_3189;    
    This work demonstrates for the first time that de novo designed miniproteins can be administered orally and reach a therapeutic target past the gut epithelial barrier. With very high potency, gut stability, and straightforward manufacturability, de novo designed minibinders are a promising new modality for orally delivered biologics.
  • ||||||||||  Tremfya (guselkumab) / J&J
    DEVELOPMENT OF A CROHN'S DISEASE MOLECULAR ACTIVITY SCORE TO IDENTIFY REGION-SPECIFIC CHRONICALLY INFLAMED AND NON-INFLAMED PROCESSES (Hall A) -  Mar 14, 2024 - Abstract #DDW2024DDW_3185;    
    P2/3
    Application of the MAS to identify inflamed tissue enabled identification of key immune and inflammatory related processes across the ileum and colon that were associated with the IL-23 pathway, and baseline regional endoscopic and histologic severity. By identifying inflamed baseline samples, molecular changes associated with treatment can be more accurately defined in future analyses to better understand regional heterogeneity in CD.